Tag: mdcTJK
MedinCell – Partner Teva announces the end of patient recruitment in the phase 3 clinical study of mdc-TJK, long-acting injectable treatment of olanzapine – 01/09/2024 at 7:20 p.m.
Teva Pharmaceuticals Industries Ltd., announced at the JP Morgan Healthcare Conference that it has successfully completed recruitment in Europe and the United States of the planned 640 participants in the…
MedinCell: favorable characteristics of data from a phase 1 study of mdc-TJK – 05/22/2023 at 08:19
(AOF) – MedinCell announces that data from the Phase 1 study conducted by its partner Teva Pharmaceuticals of mdc-TJK, an investigational long-acting subcutaneous formulation of olanzapine for patients with schizophrenia,…